161 related articles for article (PubMed ID: 24211314)
21. Response to flecainide test in Andersen-Tawil syndrome with incessant ventricular tachycardia.
Fernández M; Marín MDR; Fernández-Armenta J; Mora-López F; Fernández Rivero R; Berruezo A; Cano Calabria L; Vázquez García R
Pacing Clin Electrophysiol; 2018 Apr; 41(4):429-432. PubMed ID: 29023786
[No Abstract] [Full Text] [Related]
22. Opposite change with ischaemia in the antifibrillatory effects of class I and class IV antiarrhythmic drugs resulting from the alteration in ion transmembrane exchanges related to depolarization.
Aupetit JF; Bui-Xuan B; Kioueh I; Loufoua J; Frassati D; Timour Q
Can J Physiol Pharmacol; 2000 Mar; 78(3):208-16. PubMed ID: 10721812
[TBL] [Abstract][Full Text] [Related]
23. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
24. [Ion channels and arrhythmias].
Borchard U; Hafner D
Z Kardiol; 2000; 89 Suppl 3():6-12. PubMed ID: 10810780
[TBL] [Abstract][Full Text] [Related]
25. [Molecular genetic diagnostics of the cause of ventricular arrhythmias in children].
Brøndberg AK; Bjerre JV; Nielsen JC; Jensen HK
Ugeskr Laeger; 2015 Sep; 177(38):V04150366. PubMed ID: 26376421
[TBL] [Abstract][Full Text] [Related]
26. Short-term response to phenytoin sodium in Andersen-Tawil syndrome-1 with a cardiac-dominant phenotype.
Rai MK; Pai R; Prabhu MA; Pasha SW; Kedambadi RC; Kamath P; Augustine AJ; Bhavani GS; Girisha KM
Pacing Clin Electrophysiol; 2019 Feb; 42(2):201-207. PubMed ID: 30516834
[TBL] [Abstract][Full Text] [Related]
27. Safe and effective pharmacologic management of arrhythmias.
Razavi M
Tex Heart Inst J; 2005; 32(2):209-11. PubMed ID: 16107117
[No Abstract] [Full Text] [Related]
28. Reduction of complex ventricular ectopy and improvement in exercise capacity with flecainide therapy in Andersen-Tawil syndrome.
Fox DJ; Klein GJ; Hahn A; Skanes AC; Gula LJ; Yee RK; Subbiah RN; Krahn AD
Europace; 2008 Aug; 10(8):1006-8. PubMed ID: 18621769
[TBL] [Abstract][Full Text] [Related]
29. Oral verapamil effectively suppressed complex ventricular arrhythmias and unmasked U waves in a patient with Andersen-Tawil syndrome.
Erdogan O; Aksoy A; Turgut N; Durusoy E; Samsa M; Altun A
J Electrocardiol; 2008; 41(4):325-8. PubMed ID: 18353348
[TBL] [Abstract][Full Text] [Related]
30. Should a cardioverter-defibrillator be implanted in an Andersen-Tawil syndrome patient with severe ventricular arrhythmias and syncope?
Bienias P; Kostera-Pruszczyk A; Bieganowska K; Miszczak-Knecht M; Pruszczyk P
Kardiol Pol; 2014; 72(8):755. PubMed ID: 25155849
[No Abstract] [Full Text] [Related]
31. Early termination of spiral wave reentry by combined blockade of Na+ and L-type Ca2+ currents in a perfused two-dimensional epicardial layer of rabbit ventricular myocardium.
Ishiguro YS; Honjo H; Opthof T; Okuno Y; Nakagawa H; Yamazaki M; Harada M; Takanari H; Suzuki T; Morishima M; Sakuma I; Kamiya K; Kodama I
Heart Rhythm; 2009 May; 6(5):684-92. PubMed ID: 19303369
[TBL] [Abstract][Full Text] [Related]
32. [Andersen-Tawil syndrome. Efficacy of class IC drugs].
Makarov LM; Komoliatova VN; Kolosov VO; Fedina NN; Solokhin IuA
Kardiologiia; 2013; 53(1):91-6. PubMed ID: 23548357
[TBL] [Abstract][Full Text] [Related]
33. Effect of flecainide on T-wave alternans in Andersen-Tawil syndrome.
Hayashi H; Kawaguchi T; Horie M
Ann Noninvasive Electrocardiol; 2014 Jul; 19(4):383-6. PubMed ID: 25040481
[No Abstract] [Full Text] [Related]
34. [Clinical use of calcium blockers].
Ikeguchi S; Kawai C
Nihon Rinsho; 1985 Nov; 43(11):2435-9. PubMed ID: 2418227
[No Abstract] [Full Text] [Related]
35. [Calcium channel antagonists and arrhythmias].
Takahashi N; Saikawa T
Clin Calcium; 2005 Oct; 15(10):1651-5. PubMed ID: 16199910
[TBL] [Abstract][Full Text] [Related]
36. Sudden cardiac death in Andersen-Tawil syndrome.
Peters S; Schulze-Bahr E; Etheridge SP; Tristani-Firouzi M
Europace; 2007 Mar; 9(3):162-6. PubMed ID: 17272325
[TBL] [Abstract][Full Text] [Related]
37. Catheter ablation of frequent monomorphic ventricular arrhythmias in Andersen-Tawil syndrome: case report and focused literature review.
Keegan R; Onetto L; Gregorietti F; Urruti R; Di Biase L
J Interv Card Electrophysiol; 2023 Apr; 66(3):729-736. PubMed ID: 34665385
[TBL] [Abstract][Full Text] [Related]
38. Lack of any cardiac involvement in a patient with Andersen-Tawil syndrome associated with the c.574A→G mutation in KCNJ2.
Modoni A; Bianchi ML; Vitulano N; Pagliarani S; Perna F; Sanna T; Rizzo V; Silvestri G
Cardiology; 2011; 120(4):200-3. PubMed ID: 22286118
[TBL] [Abstract][Full Text] [Related]
39. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
Rosso R; Kalman JM; Rogowski O; Diamant S; Birger A; Biner S; Belhassen B; Viskin S
Heart Rhythm; 2007 Sep; 4(9):1149-54. PubMed ID: 17765612
[TBL] [Abstract][Full Text] [Related]
40. Ventricular bigeminy characterization in 24-h Holter monitoring from Andersen-Tawil patients: An initial proof of concept versus patients with ischemic heart disease.
Lerma C; Manzano-Cabada J; Valencia P; Márquez-Murillo MF
J Electrocardiol; 2023; 77():37-40. PubMed ID: 36584547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
